BRIEF—Luqa and Ferrer to collaborate in China

Shanghai’s Luqa Pharmaceuticals has reached a deal with Spanish drugmaker Ferrer Internacional to develop and commercialize ozenoxacin in China and Hong Kong.

Branded variously as Ozanex, Dubine and Xepi, the product is an antibiotic treatment for the highly infectious skin disease impetigo, approved in the USA, Canada and 11 countries in Europe.

The firms will work together to seek approval in China, building on a strategic collaboration agreed in October 2018 related to the development of products from the Ferrer pipeline.